Matinas BioPharma Holdings (MTNB) Profit After Tax (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Profit After Tax of -$1.9 million for Q1 2026, down 16.0% year-over-year from -$2.3 million in Q1 2025, and down 48.45% quarter-over-quarter from -$1.3 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Profit After Tax (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Profit After Tax for 14 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 16.0% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$10.0 million (up 49.91% YoY), while the FY2025 annual figure was -$10.3 million, up 57.34% from the prior year.
- Profit After Tax slipped to -$1.9 million in Q1 2026 per MTNB's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$1.3 million in Q4 2025 and bottomed at -$8.4 million in Q4 2024.
- Historically, Profit After Tax has averaged -$4.6 million across 5 years, with a median of -$5.5 million in 2022.
- Annual changes were most pronounced in 2023 — Profit After Tax plunged 82.0% — and 2025, when it jumped 84.66%.
- Matinas BioPharma Holdings' Profit After Tax stood at -$2.8 million in 2022, then slumped by 82.0% to -$5.2 million in 2023, then slumped by 62.93% to -$8.4 million in 2024, then surged by 84.66% to -$1.3 million in 2025, then slumped by 48.45% to -$1.9 million in 2026.
- Business Quant data shows MTNB's Profit After Tax at -$1.9 million in Q1 2026, -$1.3 million in Q4 2025, and -$1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | -1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.33 Mn |
| Mar 31, 2026 | -1.92 Mn |
| Dec 31, 2025 | -1.29 Mn |
| Sep 30, 2025 | -1.53 Mn |
| Jun 30, 2025 | -5.25 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Dec 31, 2024 | -8.43 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -5.64 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Dec 31, 2023 | -5.18 Mn |
| Sep 30, 2023 | -6.06 Mn |
| Jun 30, 2023 | -6.06 Mn |
| Mar 31, 2023 | -5.51 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Sep 30, 2022 | -5.46 Mn |
| Jun 30, 2022 | -5.92 Mn |
| Mar 31, 2022 | -5.98 Mn |
| Dec 31, 2021 | -6.47 Mn |
| Sep 30, 2021 | -6.89 Mn |